Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Antiviral Research

Volumn 45, Issue 2, 2000, Pages 135-147

  Bray, Mike ^a   Driscoll, John ^b   Huggins, John W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiviral therapy; Ebola virus; Filovirus; S Adenosyl L homocysteine hydrolase

Indexed keywords

3 DEAZAARISTEROMYCIN; 3 DEAZANEPLANOCIN A; ADENOSINE DERIVATIVE; ADENOSYLHOMOCYSTEINASE; ADENOSYLHOMOCYSTEINASE INHIBITOR; ANTIVIRUS AGENT; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EBOLA VIRUS; EXPERIMENTAL INFECTION; FEMALE; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TOXICITY TESTING; VERO CELL; VIREMIA; VIRUS INFECTION;

ANIMALIA; EBOLA VIRUS; MARBURG-LIKE VIRUSES;

EID: 0034096583     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00066-8     Document Type: Article

References (39)

1. M. Bray J.W. Huggins Antiviral therapy of haemorrhagic fevers and arbovirus infections Antiviral Ther. 3 1998 53 79
2. M. Bray K. Davis T. Geisbert C. Schmaljohn J.W. Huggins A mouse model for evaluation of Ebola prophylaxis and therapy J. Infect. Dis. 178 1998 651 661
3. B.M. Connolly K. Steele K.J. Davis T.W. Geisbert W.M. Kell N.K. Jaax P.B. Jahrling Pathogenesis of experimental Ebola virus infection in guinea pigs J. Infect. Dis. 179 Suppl. 1 1999 S203 S217
4. R.A. Coulombe Jr J.M. Huie R.P. Sharma J.W. Huggins Pharmacokinetics of the antiviral agent carbocyclic 3-deazaadenosine Drug Metab. Dispos. 21 1993 555 559
5. R.A. Coulombe Jr R.P. Sharma J.W. Huggins Pharmacokinetics of the antiviral agent 3-deazaneplanocin A Eur. J. Drug Metab. Pharmacokinet. 20 1995 197 202
6. E. De Clercq S -Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents Biochem. Pharmacol. 36 1987 2567 2575
7. E. De Clercq Carbocyclic adenosine analogues as S -adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances Nucleosides Nucleotides 17 1998 625 634
8. E. De Clercq J.A. Montgomery Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine Antiviral Res. 3 1983 17 24
9. E. De Clercq D. Bergstrom A. Holy J. Montgomery Broad-spectrum antiviral activity of adenosine analogues Antiviral Res. 4 1984 119 133
10. E. De Clercq M. Cools J. Balzarini V.E. Marquez D.R. Borcherding R.T. Borchardt J.C. Drach S. Kitaoka T. Konno Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives Antimicrob. Agents Chemother. 33 1989 1291 1297
11. T.W. Geisbert P.B. Jahrling Differentiation of filoviruses by electron microscopy Virus Res. 39 1995 129 150
12. R.I. Glazer M.C. Knode C.K. Tseng D.R. Haines V.E. Marquez 3-Deazaneplanocin A: a new inhibitor of S -adenosylhomocysteine synthesis and its effects in human colon carcinoma cells Biochem. Pharmacol. 35 1986 4523 4527
13. M.J.M. Hitchcock H.S. Jaffe J.C. Martin R.J. Stagg Cidofovir, a new agent with potent anti-herpesvirus activity Antiviral Chem. Chemother. 7 1996 115 127
14. J.W. Huggins Z. Zhang T.I. Monath Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S -adenosylhomocysteine hydrolase inhibitors Antiviral Res. Suppl. 1 1995 122
15. J.W. Huggins Z.X. Zhang M. Bray Antiviral drug therapy of filovirus infections: S -adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model J. Infect. Dis. 179 Suppl. 1 1999 S240 S247
16. N. Jaax T.W. Geisbert A. Vogel M. Topper P. Jahrling Experimental infection of rhesus monkeys by oral and conjunctival route of exposure Arch. Pathol. Lab. Med. 120 1996 140 155
17. P.B. Jahrling J. Geisbert J.R. Swearengen G.P. Jaax T. Lewis J.W. Huggins J.J. Schmidt J.W. LeDuc C.J. Peters Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses Arch. Virol. Suppl. 11 1996 135 140
18. P. Jahrling T. Geisbert J. Geisbert J. Swearengen M. Bray N. Jaax J. Huggins J. LeDuc C.J. Peters Evaluation of immune globulin and recombinant interferon α-2b for treatment of experimental Ebola virus infections J. Infect. Dis. 179 Suppl. 1 1999 S224 S234
19. K.M. Johnson J.V. Lange P.A. Webb F.A. Murphy Isolation and partial characterization of a new virus causing acute haemmorhagic fever in Zaire Lancet 12 1977 569 571
20. N. Kudoyarova-Zubavichene N. Sergeyev A.and Chepurnov S. Netesov Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections J. Infect. Dis. 179 Suppl. 1 1999 S218 S223
21. L. Lambert K. Frondorf J.and Berling J. Wolos Effects of an S -adenosyl- l -homocysteine hydrolase inhibitor on murine macrophage activation and function Immunopharmacology 29 1995 121 127
22. S. Liu M. Wolfe R. Borchardt Rational approaches to the design of antiviral agents based on S -adenosyl- l -homocysteine hydrolase as a molecular target Antivir. Res. 19 1992 247 265
23. J.B. McCormick S.P. Bauer L.H. Elliott P.A. Webb K.M. Johnson Biologic differences between strains of Ebola virus from Zaire and Sudan J. Infect. Dis. 147 1983 264 267
24. V.V. Mikhailov I.V. Borisevich N.K. Chernikova N.V. Potryvaeva V.P. Krasnianskii The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever Vopr. Virusol. 39 1994 82 84
25. J.B. Moe R.D. Lambert H.W. Lupton Plaque assay for Ebola virus J. Clin. Microbiol. 13 1981 791 793
26. J.A. Montgomery S.J. Clayton H.J. Thomas W.M. Shannon G. Arnett A.J. Bodner I.K. Kion G.L. Cantoni P.K. Chiang Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S -adenosylhomocysteine hydrolase as a pharmacological target J. Med. Chem. 25 1982 626 629
27. M.Z.W. Parmely C. Edwards D. Borcherding R. Silverstein D. Morrison Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge J. Immunol. 151 1993 389 396
28. C.J. Peters J. LeDuc An introduction to Ebola: the virus and the disease J. Infect. Dis. 179 Suppl. 1 1999 ix xvi
29. C.J. Peters P. Rollin T.G. Ksiazek F.A. Murphy Filoviridae: Marburg and Ebola viruses B.N. Fields D.M. Knipe P.M. Howley Fields Virology 1996 Lippincott–Raven New York 1161 1176
30. E.K.I. Ryabchikova S. Netesov Animal pathology of filovirus infections Curr. Topics Microbiol. Immunol. 235 1998 147 173
31. A. Sanchez T.G. Ksiazek P.E. Rollin C.J. Peters S.T. Nichol A.S. Khan B.W. Mahy Reemergence of Ebola virus in Africa Emerg. Infect. Dis. 1 1995 96 97 [editorial]
32. J. Schmidt R. Bomford X. Gao J. Rhodes 3-Deazaadenosine — an inhibitor of interleukin 1 production by human peripheral blood monocytes Int. J. Immunopharmacol. 12 1990 89 97
33. C.K.H. Tseng V.E. Marquez R.W. Fuller B.M. Goldstein D.R. Haines H. Mcpherson J.L. Parsons W.M. Shannon G. Arnett Synthesis of 3 deazaneplanocin a a powerful inhibitor of S -adenosylhomocysteine hydrolase with potent and selective in-vitro and in-vivo antiviral activities J. Med. Chem. 32 1989 1442 1446
34. G. Van der Groen W. Jacob S.R. Pattyn Ebola virus virulence for newborn mice J. Med. Virol. 4 1979 239 240
35. M. Wolfe R. Borchardt S -Adenosyl- l -homocysteine hydrolase as a target for antiviral chemotherapy Med. Chem. 34 1991 1523 1530
36. J. Wolos K. Frondorf R. Esser Immunosuppression mediated by an inhibitor of S -adenosyl- l -homocysteine hydrolase J. Immunol. 151 1993 526 534
37. J. Wolos K. Frondorf G. Davis E. Jarvi J. McCarthy T. Bowlin Selective inhibition of T cell activation by an inhibitor of S -adenosyl- l -homocysteine hydrolase J. Immunol. 150 1993 3264 3273
38. P.R. Wyde M.W. Ambrose H.L. Meyer C.L. Zolinski B.E. Gilbert Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats Antiviral. Res. 14 1990 215 225
39. Zaki, S.R, 1998. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 235, 97–116.